 |
 |
 |
 |
 |
 |
 |
 |
Our diagnostic assays can speed and reduce the cost of diagnosis in
people with AD, increase the certainty of the AD diagnosis, and assess
the risk of developing dementia in people with mild cognitive impairment
(MCI). They can also guide patient-drug selection for improved drug
response in clinical trials and in practice as companion diagnostic or
theragnostic tests.
From early 2009, our biomarkers will be validated and we will provide
biomarker assay services commercially to the biopharmaceutical
industry for use in preclinical and clinical development. In parallel to
providing these services, we will seek regulatory approval of products
incorporating our biomarkers, first as research kits, then as companion
diagnostic tests, and finally as clinical diagnostic predictors of AD risk.
